EGFR and non-small cell lung carcinoma: These findings suggested that EGFR gene amplification may be responsible for the resistance of NSCLC–LM patients to EGFR-TKIs, and the addition of nimotuzumab will be another choice for the treatment of EGFR-mutated NSCLC patients with LM.